Q-omics provides the consensus-scored MYLK profile across patient tissues and cancer cell-line models. MYLK expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MYLK is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, MYLK protein abundance shows 30,247 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, BLCA, and LSCC as cancer lineages where MYLK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYLK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYLK survival associations across molecular data types. MYLK RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYLK RNA expression–survival associations across cancer types. High MYLK expression shows unfavorable associations in BLCA and KIRP, but favorable associations in KIRC, LUAD, THCA and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MYLK RNA expression.
This table summarizes MYLK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MYLK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYLK shows lower tumor expression in BLCA, COAD, LUSC, KICH, KIRP and LUAD. The BLCA box plot shows higher MYLK RNA expression in normal versus tumor tissue (log2 FC = −4.837, t-test p < 0.001).
This table shows molecular features associated with MYLK in patient tissues and cancer cell lines. In patient samples, MYLK shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYLK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BONE.
